Kayla Temple
-
Vanderbilt honors 2025 Master Innovators who drive breakthrough research and commercial impact
Five exceptional Vanderbilt faculty members have been named 2025 Master Innovators for their extraordinary contributions to translating research into commercial applications that have significant societal impact. The 2025 honorees represent diverse fields from infectious disease therapeutics to neuroscience drug discovery and biomedical engineering. Read MoreNov 10, 2025
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials. Read MoreDec 4, 2023